1. Home
  2. FHB vs CELC Comparison

FHB vs CELC Comparison

Compare FHB & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Hawaiian Inc.

FHB

First Hawaiian Inc.

HOLD

Current Price

$23.91

Market Cap

3.2B

Sector

Finance

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$114.28

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FHB
CELC
Founded
1858
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.1B
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
FHB
CELC
Price
$23.91
$114.28
Analyst Decision
Hold
Strong Buy
Analyst Count
6
8
Target Price
$27.50
$106.63
AVG Volume (30 Days)
1.2M
527.9K
Earning Date
05-01-2026
01-01-0001
Dividend Yield
4.36%
N/A
EPS Growth
22.91
N/A
EPS
2.20
N/A
Revenue
$880,788,000.00
N/A
Revenue This Year
$6.90
N/A
Revenue Next Year
$3.36
N/A
P/E Ratio
$10.85
N/A
Revenue Growth
8.94
N/A
52 Week Low
$20.32
$7.58
52 Week High
$28.35
$120.32

Technical Indicators

Market Signals
Indicator
FHB
CELC
Relative Strength Index (RSI) 33.09 56.01
Support Level $23.09 $97.75
Resistance Level $25.16 $114.54
Average True Range (ATR) 0.68 5.14
MACD -0.12 0.36
Stochastic Oscillator 14.37 63.53

Price Performance

Historical Comparison
FHB
CELC

About FHB First Hawaiian Inc.

First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: